Tilray Brands (TLRY) | Financial Analysis & Statements
Tilray Brands Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Aug 2025Income Metrics
Revenue
209.5M
Gross Profit
57.5M
27.43%
Operating Income
-10.9M
-5.19%
Net Income
1.5M
0.72%
EPS (Diluted)
$0.00
Balance Sheet Metrics
Total Assets
2.1B
Total Liabilities
562.0M
Shareholders Equity
1.5B
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
9.6M
Free Cash Flow
-10.9M
Revenue & Profitability Trend
Quarter Income Flow
Aug 31, 2025
Annual Income Flow
2025
Tilray Brands Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 821.3M | 788.9M | 627.1M | 628.4M | 513.1M |
| Cost of Goods Sold | 580.7M | 565.6M | 480.2M | 511.6M | 389.9M |
| Gross Profit | 240.6M | 223.4M | 147.0M | 116.8M | 123.2M |
| Gross Margin % | 29.3% | 28.3% | 23.4% | 18.6% | 24.0% |
| Operating Expenses | |||||
| Research & Development | 284.0K | 635.0K | 682.0K | 1.5M | 830.0K |
| Selling, General & Administrative | 259.5M | 250.7M | 231.0M | 233.4M | 155.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 259.8M | 251.4M | 231.7M | 234.9M | 156.5M |
| Operating Income | -107.8M | -112.8M | -178.2M | -233.3M | -68.6M |
| Operating Margin % | -13.1% | -14.3% | -28.4% | -37.1% | -13.4% |
| Non-Operating Items | |||||
| Interest Income | 11.4M | 12.8M | 33.0M | 11.7M | 2.9M |
| Interest Expense | 41.3M | 49.3M | 46.6M | 39.7M | 30.9M |
| Other Non-Operating Income | -2.2B | -99.8M | -1.3B | -179.5M | -248.4M |
| Pre-tax Income | -2.3B | -249.0M | -1.5B | -440.7M | -345.0M |
| Income Tax | -121.0M | -26.6M | -7.2M | -6.5M | -9.0M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -2.2B | -222.4M | -1.4B | -434.1M | -336.0M |
| Net Margin % | -265.6% | -28.2% | -230.1% | -69.1% | -65.5% |
| Key Metrics | |||||
| EBITDA | 19.4M | -47.8M | -313.0M | 101.9M | -159.2M |
| EPS (Basic) | $-24.60 | $-0.33 | $-2.35 | $-0.90 | $-1.25 |
| EPS (Diluted) | $-24.60 | $-0.33 | $-2.35 | $-0.90 | $-1.25 |
| Basic Shares Outstanding | 89032601 | 673951515 | 617982589 | 482368889 | 446440641 |
| Diluted Shares Outstanding | 89032601 | 673951515 | 617982589 | 482368889 | 446440641 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Tilray Brands Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 221.7M | 228.3M | 206.6M | 415.9M | 488.5M |
| Short-term Investments | 34.7M | 32.2M | 241.9M | 0 | - |
| Accounts Receivable | 121.5M | 101.7M | 86.2M | 95.3M | 87.3M |
| Inventory | 270.9M | 252.1M | 200.6M | 245.5M | 256.4M |
| Other Current Assets | 34.1M | 31.3M | 37.7M | 46.8M | 48.9M |
| Total Current Assets | 688.6M | 677.7M | 773.0M | 803.5M | 883.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 343.2M | 318.6M | 191.4M | 267.5M | 268.4M |
| Goodwill | 1.5B | 4.9B | 5.0B | 6.6B | 7.3B |
| Intangible Assets | 21.4M | 915.5M | 973.8M | 1.3B | 1.6B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 11.1M | 5.4M | 222.0K | 314.0K | 8.3M |
| Total Non-Current Assets | 1.4B | 3.5B | 3.5B | 4.6B | 5.1B |
| Total Assets | 2.1B | 4.2B | 4.3B | 5.4B | 6.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 107.3M | 105.4M | 70.8M | 68.6M | 57.7M |
| Short-term Debt | 28.9M | 39.0M | 224.3M | 92.6M | 49.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 16.1M | 18.3M | 18.0M | 30.3M | 138.8M |
| Total Current Liabilities | 280.3M | 299.2M | 433.0M | 280.3M | 401.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 299.8M | 348.4M | 365.9M | 531.2M | 889.1M |
| Deferred Tax Liabilities | 3.7M | 130.9M | 167.4M | 196.6M | 265.8M |
| Other Non-Current Liabilities | 855.0K | 90.0K | 11.1M | 191.0K | 3.9M |
| Total Non-Current Liabilities | 304.4M | 479.3M | 544.3M | 728.0M | 1.2B |
| Total Liabilities | 584.8M | 778.5M | 977.3M | 1.0B | 1.6B |
| Equity | |||||
| Common Stock | 106.0K | 83.0K | 66.0K | 53.0K | 46.0K |
| Retained Earnings | -4.8B | -2.7B | -2.4B | -962.9M | -486.0M |
| Treasury Stock | 0 | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.5B | 3.4B | 3.3B | 4.4B | 4.5B |
| Key Metrics | |||||
| Total Debt | 328.7M | 387.3M | 590.1M | 623.8M | 938.7M |
| Working Capital | 408.3M | 378.5M | 340.0M | 523.2M | 482.4M |
Balance Sheet Composition
Tilray Brands Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -2.2B | -222.4M | -1.4B | -434.1M | -336.0M |
| Depreciation & Amortization | 133.5M | 126.9M | 130.1M | 154.6M | 67.8M |
| Stock-Based Compensation | 24.3M | 31.8M | 39.6M | 36.0M | 17.4M |
| Working Capital Changes | -31.4M | -22.2M | -8.8M | -51.6M | -64.1M |
| Operating Cash Flow | -2.1B | -69.8M | -1.1B | -371.9M | -278.4M |
| Investing Activities | |||||
| Capital Expenditures | -26.1M | -20.7M | -16.5M | -21.9M | -32.3M |
| Acquisitions | -18.1M | -60.6M | -26.7M | 326.0K | 66.6M |
| Investment Purchases | - | - | -241.9M | 0 | 0 |
| Investment Sales | - | - | 0 | 0 | 8.4M |
| Investing Cash Flow | -44.2M | -81.4M | -285.1M | -21.5M | 46.1M |
| Financing Activities | |||||
| Share Repurchases | 0 | 0 | -1.2M | -8.7M | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 3.4M | 54.2M | 146.3M | 0 | 102.8M |
| Debt Repayment | -18.7M | -132.6M | -209.8M | -133.0M | -65.6M |
| Financing Cash Flow | 133.5M | -75.2M | 70.2M | 122.8M | 124.2M |
| Free Cash Flow | -127.5M | -60.2M | -12.9M | -211.3M | -83.6M |
| Net Change in Cash | -2.1B | -226.3M | -1.3B | -270.7M | -108.1M |
Cash Flow Trend
Tilray Brands Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.27
Forward P/E
25.13
Price to Book
2.26
Price to Sales
0.95
PEG Ratio
0.00
Profitability Ratios
Profit Margin
-156.66%
Operating Margin
-52.70%
Return on Equity
-63.16%
Return on Assets
-1.47%
Financial Health
Current Ratio
2.79
Debt to Equity
63.61
Beta
2.11
Per Share Data
EPS (TTM)
$-14.63
Book Value per Share
$3.02
Revenue per Share
$8.04
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TLRY | 807.3M | -0.27 | 2.26 | -63.16% | -156.66% | 63.61 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Dynavax Technologies | 1.8B | 54.60 | 3.41 | -7.14% | -13.13% | 54.15 |
| Ani Pharmaceuticals | 1.8B | 24.08 | 3.10 | 16.16% | 8.87% | 116.19 |
| Perrigo Company plc | 1.6B | 2,818.00 | 0.55 | -38.66% | -33.51% | 131.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.






